Should troponin and creatinine kinase be routinely measured after vascular surgery?

Area of Science:

• Cardiology
• Vascular Surgery
• Biomarker Research

Background:

• Current guidelines for cardiovascular event prediction after vascular surgery in high-risk patients primarily recommend serial electrocardiograms (ECGs).
• Biomarkers like cardiac troponin I (cTn-I) and CK-MB are not routinely recommended despite their potential role in risk stratification.

Purpose of the Study:

• To investigate the efficacy of routine biomarker measurement, specifically cTn-I and CK-MB, in predicting adverse cardiovascular events (CVEs) in high-risk patients undergoing vascular surgery.
• To compare the sensitivity and predictive value of cTn-I and CK-MB for CVE detection post-operatively.

Main Methods:

• A multicenter, prospective study involving 784 high-risk patients undergoing vascular surgery.
• Serial measurements of cTn-I and CK-MB were performed at multiple time points: pre-surgery, 24, 72, and 120 hours post-surgery, pre-discharge, and upon suspected CVE onset.
• Cardiovascular events (cardiac death or myocardial infarction) were adjudicated by an endpoint committee up to 30 days post-surgery.

Main Results:

• Of 83 patients experiencing a CVE, cTn-I was positive in 42 and CK-MB in 29.
• cTn-I demonstrated higher sensitivity (50.6%) compared to CK-MB (34.9%) for predicting CVEs.
• The optimal time for cTn-I measurement with the highest positive predictive value for CVEs was 24 hours post-surgery.

Conclusions:

• Data support the routine serial measurement of cTn-I after vascular surgery for improved prediction of adverse cardiovascular events.
• Serial cTn-I monitoring can enhance the identification and management of high-risk patients following vascular procedures.